Lyonshare Marketing LLC

West Analytical Services offers product testing, development and packaging solutions for the pharmaceutical industry throughout the world. It assists clients in the areas of laboratory analysis associated with meeting drug product, stability, container closure and packaging regulatory guidelines. The company specializes in the fields of product validation, release, administration systems, devices and package testing. It offers process development, problem resolution, migration testing, material extraction, toxicological evaluation and profiling services. The company provides services to pharmaceutical, medical device and personal care product companies, such as Abbott Laboratories, Baxter International, GlaxoSmithKline, Warner-Lambert, Johnson & Johnson, Merck & Company and Procter & Gamble. West Analytical Services is a part of West Pharmaceutical Services, which was founded in 1923 and offers drug safety administration solutions for the pharmaceutical industry.

ECS Underwriting Inc. in Exton, PA offers the Q E Program, an insurance package specifically designed for small environmental consulting and contracting firms. This program provides comprehensive coverage, quick insurance quotes, and an easier application process, combining General Liability, Professional Liability, and Contractor's Pollution Legal Liability (CPL) coverages under one liability. With policies ranging from $500,000 to $5 million in limits of liability, clients can choose either claims-made or occurrence form coverage. In addition to insurance, ECS Underwriting also offers risk control and claims administration services, as well as various other services such as employee health and safety training, environmental auditing, and emergency response planning.Generated from the website

Hybridon is engaged in the discovery, development and commercialization of novel therapeutics based on synthetic DNA for the treatment of cancer, asthma and allergies, and infectious diseases. The company's drug candidates are designed to modulate immune responses through Toll-like receptor 9 and antisense. Its discovery platforms to identify drug candidates are based on DNA chemistries developed at Hybridon. The company, founded by the Worcester Foundation for Biomedical Research, was incorporated in 1989 for the purpose of engaging in the discovery and development of novel therapeutics through the application of synthetic DNA. Headquartered in Cambridge, Mass., Hybridon is a publicly owned company that employs nearly 30 people.